Devang Shah. My firm name is DD Enterprise. I have only one question to the management regarding what are the key triggers to look into the company for the next three- four quarters? Is it going to come from Biocon JV or it is from Semaglutide, or from which product line or from which of the things we can consider, the next three -four quarters can be looked at?
Okay. So now, there would be no raising of debt in the next two, three years, by acquisitions or is there any plan to do some acquisitions also?